Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Patient-Reported Outcomes of BMT CTN 1703: A Randomized Phase III Study for Gvhd Prophylaxis - a Quality of Life Evaluation

Blood (2023) 142 (Supplement 1): 897.

https://doi.org/10.1182/blood-2023-187859

Published: 2023

Journal Articles

Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil As the New Standard for Graft-Versus-Host Disease (GVHD) Prophylaxis in Reduced Intensity Conditioning: Results from Phase III BMT CTN 1703

Blood (2022) 140 (Supplement 2): LBA-4.

https://doi.org/10.1182/blood-2022-171463

Published: 2022

Journal Articles

Impact of Autologous Hematopoietic Cell Transplant (HCT) Followed By Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance in Increasing Multiple Myeloma (MM) Immunity (BMT CTN 1401)

Blood (2021) 138 (Supplement 1): 899.

https://doi.org/10.1182/blood-2021-149659

Published: 2021

Journal Articles

Amphiregulin Improves Stratification of the Refined Minnesota Acute Graft-Versus-Host Disease Risk Score: Results from BMT CTN 0302/0802

Blood (2017) 130 (Supplement 1): 72.

https://doi.org/10.1182/blood.V130.Suppl_1.72.72

Published: 2017

Journal Articles

Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post–allogeneic HCT

Mohammad Abu Zaid, Juan Wu, Cindy Wu, Brent R. Logan, Jeffrey Yu, Corey Cutler, Joseph H. Antin, Sophie Paczesny, Sung Won Choi

Blood (2017) 129 (2): 162–170.

https://doi.org/10.1182/blood-2016-08-735324

Published: 2017

Includes: Supplemental data

Journal Articles

Follistatin and Endoglin: Potential Biomarkers of Endothelial Damage and Non-Relapse Mortality after Myeloablative Allogeneic Hematopoietic Cell Transplantation in Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0402

Laura F. Newell, MD, Todd E. DeFor, MS, Corey S. Cutler, MD MPH, Michael R. Verneris, MD, Bruce R. Blazar, MD, Joseph H. Antin, MD, Alan Howard, PhD, Juan Wu, Margaret L. MacMillan, MD, Angela Panoskaltsis-Mortari, PhD, Daniel J. Weisdorf, MD, Shernan G. Holtan, MD

Blood (2016) 128 (22): 63.

https://doi.org/10.1182/blood.V128.22.63.63

Published: 2016

Journal Articles

A trial of unrelated donor marrow transplantation for children with severe sickle cell disease

Blood (2016) 128 (21): 2561–2567.

https://doi.org/10.1182/blood-2016-05-715870

Published: 2016

Includes: Supplemental data

Journal Articles

Results of a Phase III Randomized, Multi-Center Study of Allogeneic Stem Cell Transplantation after High Versus Reduced Intensity Conditioning in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML): Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0901

Blood (2015) 126 (23): LBA-8.

https://doi.org/10.1182/blood.V126.23.LBA-8.LBA-8

Published: 2015

Journal Articles

A Multicenter Phase II Trial of Unrelated Donor Reduced Intensity Bone Marrow Transplantation for Children with Severe Sickle Cell Disease (SCURT): Results of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0601) Study

Shalini Shenoy, MD, Mary Eapen, MBBS, Juan Wu, Mark C. Walters, MD, John E. Levine, MD MS, Brent Logan, PhD, Iris D. Gersten, MS, Naynesh R. Kamani, MD

Blood (2015) 126 (23): 619.

https://doi.org/10.1182/blood.V126.23.619.619

Published: 2015

Journal Articles

5 Year Results of BMT CTN 0201: Unrelated Donor Bone Marrow Is Associated with Better Psychological Well-Being and Less Burdensome Chronic Gvhd Symptoms Than Peripheral Blood

Stephanie J. Lee, MD MPH, Brent Logan, PhD, Peter Westervelt, MD PhD, Corey S Cutler, MD MPH, Ann E Woolfrey, MD, Shakila Khan, MD, Edmund K Waller, MD PhD, Richard T. Maziarz, MD, Juan Wu, Bronwen E. Shaw, MBChB, PhD MRCP, MRCPath, Dennis L. Confer, MD, Mary M. Horowitz, MD MS, Claudio Anasetti, MD

Blood (2015) 126 (23): 270.

https://doi.org/10.1182/blood.V126.23.270.270

Published: 2015

Journal Articles

Patient-Reported Quality of Life Is an Independent Predictor of Survival after Allogeneic Hematopoietic Cell Transplantation: A Secondary Analysis from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902

William A. Wood, MD MPH, Jennifer Le-Rademacher, PhD, Mingwei Fei, MS, Brent R. Logan, PhD, Karen L Syrjala, PhD, Navneet S. Majhail, MD MS, John R. Wingard, MD, Muneer H. Abidi, MD, Nancy L. Geller, PhD, Juan Wu, MS, J. Douglas Rizzo, MD, Edward A Faber, DO, MS, Heather Jim, PhD, Paul Jacobsen, PhD, Mary M. Horowitz, MD MS, Stephanie J. Lee, MD MPH

Blood (2014) 124 (21): 206.

https://doi.org/10.1182/blood.V124.21.206.206

Published: 2014

Journal Articles

Optimized Cyclophosphamide (CY) Dosing in Combination with Fludarabine, TBI and ATG As Conditioning for Unrelated Donor Bone Marrow Transplantation (BMT) in Severe Aplastic Anemia (SAA): A Phase I/II Study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN)

Paolo Anderlini, MD, Juan Wu, MS, H. Joachim Deeg, MD, Iris Gersten, MS, Marian Ewell, ScD, Jakub Tolar, MD PhD, Joseph H. Antin, MD, Sally Arai, MD, Mitchell E. Horwitz, MD, John M. McCarty, MD, Ryotaro Nakamura, MD, Michael A. Pulsipher, MD, Roberta H. Adams, MD, Eric Leifer, PhD, Shelly L Carter, ScD, Nancy L DiFronzo, PhD, Mary M. Horowitz, MD MS, Dennis L. Confer, MD, Mary Eapen, MBBS, MS

Blood (2014) 124 (21): 541.

https://doi.org/10.1182/blood.V124.21.541.541

Published: 2014

Journal Articles

Reduced Intensity Conditioning (RIC) with Rituximab Yields Excellent Outcomes after Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Relapsed Follicuar Lymphoma (FL): A Phase II Multicenter Trial from the Blood and Marrow Transplant Network (BMT CTN 0701)

Ginna G. Laport, MD, Juan Wu, MS, Brent R. Logan, PhD, Veronika Bachanova, MD, Chitra M. Hosing, Timothy S. Fenske, MD, Walter L. Longo, MD, Steven M. Devine, MD, Auayporn P. Nademanee, MDBS, Iris Gersten, MS, Mary M. Horowitz, MD MS, Hillard M. Lazarus, MD, Marcie L Riches, MD MS

Blood (2014) 124 (21): 682.

https://doi.org/10.1182/blood.V124.21.682.682

Published: 2014

Journal Articles

Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT

Corey Cutler, Brent Logan, Ryotaro Nakamura, Laura Johnston, Sung Choi, David Porter, William J. Hogan, Marcelo Pasquini, Margaret L. MacMillan, Jack W. Hsu, Edmund K. Waller, Stephan Grupp, Philip McCarthy, Juan Wu, Zhen-Huan Hu, Shelly L. Carter, Mary M. Horowitz, Joseph H. Antin

Blood (2014) 124 (8): 1372–1377.

https://doi.org/10.1182/blood-2014-04-567164

Published: 2014

Journal Articles

Exercise and Stress Management Training For Patients Undergoing Autologous Or Allogeneic Hematopoietic Cell Transplantation. Results From Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902

Stephanie J. Lee, MD, MPH, Jennifer Le Rademacher, PhD, Heather Jim, PhD, Karen L Syrjala, PhD, John R. Wingard, MD, PhD, Brent R. Logan, PhD, Juan Wu, MS, Navneet S. Majhail, MD, MS, William A. Wood, MD, MPH, J. Douglas Rizzo, MD, Nancy L. Geller, PhD, Carrie L. Kitko, MD, Edward A. Faber, Jr., DO, MS, Muneer H. Abidi, MD, Susan E. Slater, FNP, Mary M. Horowitz, MD, MS, Paul Jacobsen, Ph.D.

Blood (2013) 122 (21): 699.

https://doi.org/10.1182/blood.V122.21.699.699

Published: 2013

Journal Articles

Tacrolimus/Sirolimus Vs. Tacrolimus/Methotrexate for Graft-Vs.-Host Disease Prophylaxis After HLA-Matched, Related Donor Hematopoietic Stem Cell Transplantation: Results of Blood and Marrow Transplant Clinical Trials Network Trial 0402

Corey Cutler, MD, MPH, FRCPC, Brent R. Logan, PhD, Ryotaro Nakamura, MD, Laura Johnston, MD, Sung W. Choi, M.D., David L Porter, MD, William J Hogan, MBBCh, Marcelo C Pasquini, MD, MS, Margaret L. MacMillan, MD, John R. Wingard, MD, Edmund K. Waller, MD, PhD, Stephan A. Grupp, MD, PhD, Philip L. McCarthy, MD, Juan Wu, MS, Zhenhuan Hu, MPH, Shelly L Carter, ScD, Mary M. Horowitz, MD, MS, Joseph H. Antin, MD

Blood (2012) 120 (21): 739.

https://doi.org/10.1182/blood.V120.21.739.739

Published: 2012

Journal Articles

Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study

John E. Levine, Brent R. Logan, Juan Wu, Amin M. Alousi, Javier Bolaños-Meade, James L. M. Ferrara, Vincent T. Ho, Daniel J. Weisdorf, Sophie Paczesny

Blood (2012) 119 (16): 3854–3860.

https://doi.org/10.1182/blood-2012-01-403063

Published: 2012

Includes: Supplemental data

Journal Articles

The role of Skp2 in hematopoietic stem cell quiescence, pool size, and self-renewal

Jing Wang, Fei Han, Juan Wu, Szu-Wei Lee, Chia-Hsin Chan, Ching-Yuan Wu, Wei-Lei Yang, Yuan Gao, Xian Zhang, Yun Seong Jeong, Asad Moten, Felipe Samaniego, Peng Huang, Quentin Liu, Yi-Xin Zeng, Hui-Kuan Lin

Blood (2011) 118 (20): 5429–5438.

https://doi.org/10.1182/blood-2010-10-312785

Published: 2011

Includes: Supplemental data

Journal Articles

Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts

Claudio G. Brunstein, Ephraim J. Fuchs, Shelly L. Carter, Chatchada Karanes, Luciano J. Costa, Juan Wu, Steven M. Devine, John R. Wingard, Omar S. Aljitawi, Corey S. Cutler, Madan H. Jagasia, Karen K. Ballen, Mary Eapen, Paul V. O'Donnell, on behalf of the Blood and Marrow Transplant Clinical Trials Network

Blood (2011) 118 (2): 282–288.

https://doi.org/10.1182/blood-2011-03-344853

Published: 2011

Journal Articles

Melphalan Containing Cytoreduction Results in a Good Overall Survival (OS) in Pediatric Patients with Relapse or Refractory AML Undergoing Unrelated Umbilical Cord Blood Transplantation (UCBT).

Vinod K. Prasad, MD, MRCP, Juan Wu, MS, Paul L. Martin, MD, PhD, Timothy A. Driscoll, MD, Suhag H. Parikh, MD, Deborah Semmel, FNP, Jerelyn Moffet, PNP, Lauren Stafford, PNP, Ann Shonkwiler, PNP, Shelly Carter, Sc.D, Paul Szabolcs, MD, Joanne Kurtzberg, MD

Blood (2006) 108 (11): 3150.

https://doi.org/10.1182/blood.V108.11.3150.3150

Published: 2006

NARROW

Patient-Reported Outcomes of BMT CTN 1703: A Randomized Phase III Study for Gvhd Prophylaxis - a Quality of Life Evaluation

Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil As the New Standard for Graft-Versus-Host Disease (GVHD) Prophylaxis in Reduced Intensity Conditioning: Results from Phase III BMT CTN 1703

Impact of Autologous Hematopoietic Cell Transplant (HCT) Followed By Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance in Increasing Multiple Myeloma (MM) Immunity (BMT CTN 1401)

Amphiregulin Improves Stratification of the Refined Minnesota Acute Graft-Versus-Host Disease Risk Score: Results from BMT CTN 0302/0802

Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post–allogeneic HCT

Follistatin and Endoglin: Potential Biomarkers of Endothelial Damage and Non-Relapse Mortality after Myeloablative Allogeneic Hematopoietic Cell Transplantation in Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0402

A trial of unrelated donor marrow transplantation for children with severe sickle cell disease

Results of a Phase III Randomized, Multi-Center Study of Allogeneic Stem Cell Transplantation after High Versus Reduced Intensity Conditioning in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML): Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0901

A Multicenter Phase II Trial of Unrelated Donor Reduced Intensity Bone Marrow Transplantation for Children with Severe Sickle Cell Disease (SCURT): Results of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0601) Study

5 Year Results of BMT CTN 0201: Unrelated Donor Bone Marrow Is Associated with Better Psychological Well-Being and Less Burdensome Chronic Gvhd Symptoms Than Peripheral Blood

Patient-Reported Quality of Life Is an Independent Predictor of Survival after Allogeneic Hematopoietic Cell Transplantation: A Secondary Analysis from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902

Optimized Cyclophosphamide (CY) Dosing in Combination with Fludarabine, TBI and ATG As Conditioning for Unrelated Donor Bone Marrow Transplantation (BMT) in Severe Aplastic Anemia (SAA): A Phase I/II Study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN)

Reduced Intensity Conditioning (RIC) with Rituximab Yields Excellent Outcomes after Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Relapsed Follicuar Lymphoma (FL): A Phase II Multicenter Trial from the Blood and Marrow Transplant Network (BMT CTN 0701)

Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT

Exercise and Stress Management Training For Patients Undergoing Autologous Or Allogeneic Hematopoietic Cell Transplantation. Results From Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902

Tacrolimus/Sirolimus Vs. Tacrolimus/Methotrexate for Graft-Vs.-Host Disease Prophylaxis After HLA-Matched, Related Donor Hematopoietic Stem Cell Transplantation: Results of Blood and Marrow Transplant Clinical Trials Network Trial 0402

Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study

The role of Skp2 in hematopoietic stem cell quiescence, pool size, and self-renewal

Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts

Melphalan Containing Cytoreduction Results in a Good Overall Survival (OS) in Pediatric Patients with Relapse or Refractory AML Undergoing Unrelated Umbilical Cord Blood Transplantation (UCBT).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only